Differences in epitope-specific antibodies to pertussis toxin after infection and acellular vaccinations

dc.contributor.authorAapo Knuutila
dc.contributor.authorTine Dalby
dc.contributor.authorAlex-Mikael Barkoff
dc.contributor.authorCharlotte Sværke Jørgensen
dc.contributor.authorKurt Fuursted
dc.contributor.authorJussi Mertsola
dc.contributor.authorKevin Markey
dc.contributor.authorQiushui He
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organizationfi=lastentautioppi|en=Paediatrics and Adolescent Medicine|
dc.contributor.organizationfi=lääketieteellinen tiedekunta|en=Faculty of Medicine|
dc.contributor.organizationfi=tyks, vsshp|en=tyks, varha|
dc.contributor.organization-code1.2.246.10.2458963.20.13290506867
dc.contributor.organization-code1.2.246.10.2458963.20.40612039509
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.converis.publication-id49141223
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/49141223
dc.date.accessioned2022-10-28T13:44:11Z
dc.date.available2022-10-28T13:44:11Z
dc.description.abstract<div> <p> <strong> Objectives: </strong> Pertussis toxin (PT) is a component of all acellular pertussis vaccines. PT must be detoxified to be included in acellular vaccines, which results in conformational changes in the functional epitopes of PTs. Therefore, induced epitope-specific antibodies to PT may vary after vaccinations or natural infections, and this information could reveal biomarkers implicated for protection and successful immunisation. </p> <p> <strong> Methods: </strong> Pertussis toxin epitope-specific antibodies in sera from 152 vaccinated children and 72 serologically confirmed patients were tested with a blocking ELISA, based on monoclonal antibodies that target protective PT epitopes. </p> <p> <strong> Results: </strong> All study groups induced considerable antibody titres to subunit 1 (S1). Of interest, S3 7E10-specific antibodies were present in patients, but not after vaccinations (<i>P</i> < 0.001). The impact of glutaraldehyde treatment of PT was visible on epitope 1D7 (S1), whereas epitopes 1B7 (S1) and 10D (S1) were more preserved. Antibodies to these epitopes were higher after three primary vaccine doses than after a single booster dose. </p> <p> <strong> Conclusion: </strong> The high amount of 7E10-specific antibodies in patients suggests this epitope might be functionally relevant in protection. The overall characteristics of epitope-specific antibodies are influenced by infection or vaccination background, by the used detoxification method of PT and by the amount of the toxin used in immunisation. </p> </div>
dc.identifier.jour-issn2050-0068
dc.identifier.olddbid183972
dc.identifier.oldhandle10024/167066
dc.identifier.urihttps://www.utupub.fi/handle/11111/41454
dc.identifier.urlhttps://doi.org/10.1002/cti2.1161
dc.identifier.urnURN:NBN:fi-fe2021042823242
dc.language.isoen
dc.okm.affiliatedauthorKnuutila, Aapo
dc.okm.affiliatedauthorBarkoff, Alex-Mikael
dc.okm.affiliatedauthorMertsola, Jussi
dc.okm.affiliatedauthorHe, Qiushui
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationinternational co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherWiley
dc.publisher.countryUnited Kingdomen_GB
dc.publisher.countryBritanniafi_FI
dc.publisher.country-codeGB
dc.relation.doi10.1002/cti2.1161
dc.relation.ispartofjournalClinical and Translational Immunology
dc.relation.issue8
dc.relation.volume9
dc.source.identifierhttps://www.utupub.fi/handle/10024/167066
dc.titleDifferences in epitope-specific antibodies to pertussis toxin after infection and acellular vaccinations
dc.year.issued2020

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
CTI2-9-e1161.pdf
Size:
924.37 KB
Format:
Adobe Portable Document Format
Description:
Publisher's version